Skip to main content
. Author manuscript; available in PMC: 2022 Sep 5.
Published in final edited form as: Mol Cancer Res. 2022 Aug 5;20(8):1260–1271. doi: 10.1158/1541-7786.MCR-21-0657

Figure 1.

Figure 1.

BAP1 mutations are correlated with increased expression of CAMs CDH1, CADM1, and SDC2. A, On the basis of BAP1 mutation and copy loss, TCGA uveal melanoma samples were stratified into BAP1 mutant and wild-type groups. Differential expression analysis was performed between BAP1 mutant (n ¼ 40) and wild-type (n ¼ 40) samples and used for performing GSEA. GSEA enrichment plots of the Hallmark epithelial to mesenchymal and KEGG CAMs) gene sets in BAP1 mutant versus wild-type groups are shown. B, A heatmap showing z-score values for the top 10 genes from the Hallmark EMT and KEGG CAMs gene sets in TCGA uveal melanoma patient tumor samples. C, CDH1, CADM1, and SDC2 gene expression from TCGA RNA-seq data in BAP1 wild-type (n ¼ 40) and mutant samples (n¼40). D, Analysis of TCGAdata for uveal melanoma patient progression-free survival according to CDH1, CADM1, and SDC2 expression, stratified by high or low median RNA expression. Log-rank test was used to determine the significance of progression-free survival (https://wiki.nci.nih.gov/plugins/servlet/mobile#content/view/24279961).